Relationship between skin disease mortality as of ICD-10 and health expenditure on purchasing power parity: A multi-country level analyses

Background: Diseases of the skin and subcutaneous tissues still cause mortality in some parts of the world. This research aimed to examine the relationship between diseases of the skin and subcutaneous tissue-related mortality as of ICD-10 and health expenditure on purchasing power parity from the World Bank Database. Material and Methods: “Domestic private health expenditure per capita, PPP (current international $)” and “Domestic general government health expenditure per capita, PPP (current international $)” were collected from the World Bank Country Data for each country in which skin and subcutaneous tissue-related mortality were reported in the World Health Organization (WHO) ICD-10 Mortality database for 1996 to 2017. Results: A total of 13 countries were reported for mortality. Male deaths related to skin and subcutaneous tissue in Oman, Sri Lanka, Azerbaijan, Turkmenistan, and Ukraine were higher than female deaths. In Seychelles, Brunei Darussalam, Syrian Arab Republic, Belarus, Kazakhstan, and Russian Federation, female deaths were higher than male deaths. The correlation direction was positive, showing that an increase in country codes in the WHO ICD-10 list causes an increase in deaths. Conclusion: Deaths resulting even from skin diseases with an extremely low mortality level have been reported. At this point, when gender is discriminated, it is seen that women and men differ significantly in skin diseases. For this reason, studies and field applications must be carried out to raise awareness about skin diseases in the male gender.

PDF

___

1. Wang X, Liu P, Xu T, Chen Y, Yu Y, et al. China-UK partnership for global health: practices and implications of the Global Health Support Programme 2012–2019. Glob Health Res Policy. 2020 Mar 20; 5: 13. doi: 10.1186/s41256–020–00134–7.
2. Foucart R, Wan C. Strategic decentralization and the provision of global public goods. Journal of Environmental Economics and Management. 2018; 92(1): 537–558.
3. Zhang J, Swartz BC. Public diplomacy to promote Global Public Goods (GPG): Conceptual expansion, ethical grounds, and rhetoric. Public Relations Review. 2009; 35(4): 382–387.
4. Boucher V, Bramoullé Y. Providing global public goods under uncertainty. Journal of Public Economics. 2010; 94(9–10): 591–603.
5. Kapur D. The Common Pool Dilemma of Global Public Goods: Lessons from the World Bank’s Net Income and Reserves. World Development. 2002; 30(3): 337–354.
6. Faunce TA. Global Public Goods. Encyclopedia of Applied Ethics (Second Edition). 2012: 523–528.
7. Cole AL, Wood WA Jr, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. JCO Oncol Pract. 2020; 20: JOP1900301. doi: 10.1200/JOP.19.00301.
8. Dean EB, French MT, Mortensen K. Food insecurity, health care utilization, and health care expenditures. Health Serv Res. 2020 Mar 18. doi: 10.1111/1475–6773.13283.
9. Patel J, Shah D, Sambamoorthi U. Healthcare Expenditures Associated with Persistent Opioid use Among Adults with Chronic Non-Cancer Pain Conditions: A Retrospective Cohort Study. J Pain Palliat Care Pharmacother. 2020 Mar 18:1–15. doi: 10.1080/15360288.2020.1734710.
10. Hay RJ. Skin Disease in the Tropics and the Lessons that can be Learned from Leprosy and Other Neglected Diseases. Acta Derm Venereol. 2020; 24. doi: 10.2340/00015555–3469.
11. Zhou S, Li Q, Wu H, Lu Q. The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases. Cell Mol Immunol. 2020; 17: 335–346. doi: 10.1038/s41423–020–0399–6.
12. Kowalewska B, Cybulski M, Jankowiak B, Krajewska-Kułak E. Acceptance of Illness, Satisfaction with Life, Sense of Stigmatization, and Quality of Life among People with Psoriasis: A Cross- Sectional Study. Dermatol Ther (Heidelb). 2020; 10: 413–430. doi: 10.1007/s13555–020–00368-w.
13. Cárcano CBM, de Oliveira CZ, Paiva BSR, Paiva CE. The Brazilian version of Skindex-16 is a valid and reliable instrument to assess the health-related quality of life of patients with skin diseases. PLoS One. 2018 Mar 22; 13(3): e0194492. doi: 10.1371/journal.pone.0194492.
14. Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020; 31: 470–475. doi: 10.1080/09546634.2020.1746734.
15. Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, et al. Patient Reported Outcomes and Quality of Life in Recessive Dystrophic Epidermolysis Bullosa: A Global Cross-sectional Survey. J Am Acad Dermatol. 2020; 19: S0190–9622(20)30442–4. doi: 10.1016/j. jaad.2020.03.028.
16. Friston D, Junttila S, Lemes JBP, Laycock H, Torres-Perez JV, et al. Leptin and fractalkine: Novel subcutaneous cytokines in burn injury. Dis Model Mech. 2020 Mar 3. pii: dmm.042713. doi: 10.1242/dmm.042713.
17. Pérez Atamoros FM et al. Evidence-based treatment for gynoid lipodystrophy: A review of the recent literature. J Cosmet Dermatol. 2018; 17: 977–983. doi: 10.1111/jocd.12555.
18. Liu YM. Population Aging, Technological Innovation, and the Growth of Health Expenditure: Evidence From Patients With Type 2 Diabetes in Taiwan. Value in Health Regional Issues. 2020; 21: 120–126.
19. Jonhston BM et al. Private health expenditure in Ireland: Assessing the affordability of private financing of health care. Health Policy. 2019; 123: 963–969.
20. Clemente J, Lázaro-Alquézar A, Montañés A. Convergence in Spanish Public health expenditure: Has the decentralization process generated disparities?. Health Policy. 123: 503–507.
21. Eggli Y, Stadelmann P, Piaget-Rossel R, Marti J. Heterogeneity in The drivers of health expenditures financed by health insurance in a fragmented health system: The case of Switzerland. Health Policy. 2019; 123: 1275–1281.
22. Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. Am Soc Clin Oncol Educ Book. 2020; 40: 1–10. doi: 10.1200/EDBK_278953.
23. Shanthi T, Sabeenian RS, Anand R. Automatic Diagnosis of Skin Diseases using Convolution Neural Network. Microprocessors and MicrosystemsIn press, journal pre-proof, Available online 19 March 2020Article 103074.
24. Yang M, Wu H, Zhao M, Chang C, Lu Q. The pathogenesis of bullous skin diseases. Journal of Translational Autoimmunity, 2019; 2(1), Article 100014.
25. ALEnezi NSA. A Method Of Skin Disease Detection Using Image Processing And Machine Learning. Procedia Computer Science, 2019; 163: 85–92.
26. Dixon LJ, Snorrason I. Prevalence and clinical characteristics of skin picking among adults with skin disease symptoms. Journal of Obsessive-Compulsive and Related Disorders. 2019; 22(1): Article 100454
27. Hassanin AM, Ismail NN, el Guindi A, Sowailam HA. The emotional burden of chronic skin disease dominates physical factors among women, adversely affecting quality of life and sexual function. Journal of Psychosomatic Research. 2018; 115: 53–57.